Stockscreener 앱 받기
25.50
1.25%
0.235
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Hedge Fund Moves: Can Castle Biosciences Inc deliver alpha2026 Top Decliners & High Return Trade Opportunity Guides - baoquankhu1.vn
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk - Yahoo Finance
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE StudySlideshow (NASDAQ:CSTL) 2026-03-23 - Seeking Alpha
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Valuation Update: Whats next for Castle Biosciences Inc stock2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Breakout Watch: Can Castle Biosciences Inc maintain its current growth rateMarket Performance Report & Safe Entry Point Identification - baoquankhu1.vn
What are the future prospects of Castle Biosciences IncWeekly Stock Report & Risk Controlled Daily Plans - baoquankhu1.vn
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock By Investing.com - Investing.com India
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock - Investing.com
Derek Maetzold Sells 650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 18,650 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CEO sells 19,300 shares under 10b5-1 plan - Stock Titan
Castle Biosciences introduces 487-gene panel to guide JAK inhibitor or Th2 therapy decisions - Traders Union
Castle Biosciences (CSTL) loses 16.8% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Risk Recap: What’s Castle Biosciences Inc.’s historical returnGold Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
Castle Biosciences (NASDAQ: CSTL) CEO sells 30,779 shares under 10b5-1 plan - Stock Titan
Big Picture: What is the implied volatility of Castle Biosciences IncQuarterly Trade Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Insider Sells $526,582.12 in Stock - MarketBeat
Castle Biosciences Officer Sells Shares - TradingView
Castle Biosciences (NASDAQ: CSTL) CCO sells 20,863 pre-planned shares - Stock Titan
Castle Biosciences (CSTL) Study Validates DecisionDx-Melanoma Te - GuruFocus
Castle Biosciences (CSTL) CEO sells 44,125 shares under 10b5-1 plan - Stock Titan
Prospective, Multi-center Study Published in Future - GlobeNewswire
New melanoma test flags patients who can skip lymph node biopsy - Stock Titan
CSTL (NASDAQ: CSTL) Form 144 shows proposed resale of 20,863 shares - Stock Titan
Derek Maetzold sells shares; CSTL (NASDAQ: CSTL) Form 144 lists large late‑2025 trades - Stock Titan
New study confirms sentinel lymph node prediction accuracy, Castle Biosciences asserts - Traders Union
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k - Investing.com Nigeria
Castle Biosciences Inc (CSTL) CFO Frank Stokes Sells 6,001 Shares - GuruFocus
Insider Selling: Castle Biosciences (NASDAQ:CSTL) CFO Sells 6,001 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Director Sells 7,403 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CFO sells 6,001 shares under 10b5-1 plan - Stock Titan
Castle Biosciences (CSTL) director exercises options and sells shares - Stock Titan
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 earnings call transcript - MSN
Aug Wrap: Whats next for Castle Biosciences Inc stockVolume Spike & Expert Verified Movement Alerts - baoquankhu1.vn
Death Cross: Will Castle Biosciences Inc benefit from current market trendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Castle Biosciences, Inc. (CSTL) reports Q4 loss, beats revenue estimates - MSN
Castle Biosciences, Inc. (CSTL) expected to beat earnings estimates: What to know ahead of Q4 release - MSN
How Castle Biosciences (CSTL) Story Is Shifting With New Revenue Targets And Fair Value - Yahoo Finance
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k By Investing.com - Investing.com UK
Frank Stokes Sells 7,000 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences (CSTL) CCO logs RSU grant, conversions and tax share withholdings - Stock Titan
Castle Biosciences (CSTL) CEO details RSU grants, conversions and tax share disposals - Stock Titan
Castle Biosciences: Interview With Founder, CEO, And President Derek Maetzold About The Molecular Diagnostics Company - Pulse 2.0
Castle Biosciences Stock Hits Day Low of $27.22 Amid Price Pressure - Markets Mojo
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - The Manila Times
Melanoma test may let some patients skip lymph node surgery - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Lowered to Hold Rating by Zacks Research - MarketBeat
Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - Bitget
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Bitget
Morgan Stanley lists 7,000 CSTL RSU shares for sale (CSTL) - Stock Titan
CSTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
0.97%
0.33%
자본화:
|
볼륨(24시간):